Huguier M, Chastang C, Houry S, Sima A M, Berhouet H, Chevret S
Department of Surgery, Hôpital Tenon, Université Paris VI, France.
Am J Surg. 1997 Jul;174(1):11-5. doi: 10.1016/S0002-9610(97)00023-8.
The purpose of this study was to compare the time to pelvic recurrence and survival after sphincter-saving resection (SSR) or abdominoperineal resection (APR).
Out of the 119 patients with a cancer of the midrectum, 43 had undergone a SSR and 76 an APR for cure. To eliminate bias of a nonrandomized retrospective comparison, an adjustment for baseline prognostic covariates was used.
Pelvic recurrence rates and survival distribution according to the type of resection did not differ significantly, with P values of 0.31 and 0.95, respectively, by the log-rank test. The Cox regression model incorporated nine binary covariates and the treatment group. Given these nine covariates, treatment did not influence either pelvic recurrence (adjusted P value = 0.62, relative risk = 0.78) or overall survival (adjusted P value = 0.89, relative risk = 1.05).
These results suggest that, in patients with cancer of the midrectum treated by SSR or APR, recurrence and survival rates are similar.
本研究的目的是比较保留括约肌切除术(SSR)或腹会阴联合切除术(APR)后盆腔复发时间和生存率。
在119例中直肠癌患者中,43例行SSR,76例行APR以治愈疾病。为消除非随机回顾性比较的偏差,对基线预后协变量进行了校正。
根据切除类型的盆腔复发率和生存分布无显著差异,对数秩检验的P值分别为0.31和0.95。Cox回归模型纳入了9个二元协变量和治疗组。考虑这9个协变量后,治疗对盆腔复发(校正P值 = 0.62,相对风险 = 0.78)或总生存(校正P值 = 0.89,相对风险 = 1.05)均无影响。
这些结果表明,在接受SSR或APR治疗的中直肠癌患者中,复发率和生存率相似。